Full Press Release Details
Reports Second Quarter 2025 Financial Results
2025 Kicks Off AI Nose's Growing Commercial Momentum with First Senior Care Revenue and New Strategic Partnerships
Nose 90-Day Roadmap to Power 2H 2025, With First Multi-Year $2.1M Order and Traction Across Robotics, Semiconductors, and Smart Manufacturing
DIEGO, CA/ ACCESSWIRE/ August 13, 2025/ Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a
leader in AI-driven scent digitization, today announced its financial results for the second quarter ended June 30, 2025.
(Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "We're thrilled that our
proprietary AI-powered scent digitization platform, AI Nose, has entered the commercial execution phase. The first half of 2025 marked
a strategic inflection point as we successfully transitioned from R&D to revenue-generating deployment in Japan. With new real-world
pilot programs underway and a clear path to scaled adoption, we've set the stage for the second half with accelerating momentum
and expanding commercial traction."
increasing integration of AI across multiple industries strongly reinforces our strategic focus on AI-driven SmellTech. According to
third party research, demand for electronic nose is growing in healthcare, environmental monitoring, and industrial automation-key
sectors where AI Nose is already gaining momentum. Through strategic partnerships, we're expanding AI Nose into a multi-industry
deployment ecosystem. I believe our expanding ecosystem both broadens our scent database and enhances our smell language models ("SLMs"),
paving the way for a SmellTech-as-a-Service subscription model. Designed to generate scalable, recurring revenue, this model supports
high-value applications such as scent analytics, predictive monitoring, and digital Smell ID profiling-extending value well beyond
very excited about AI Nose's increasing momentum in the industrial market. Earlier this month, we've secured our first three-year
subscription order valued at $2.1 million for first deployment of AI Nose in semiconductor manufacturing setting. It is also our second
commercial success, following first revenue in the senior care sector during 1Q 2025. Following the software-hardware integration of
AI Nose into our first robotic partner's robots, we are launching pilot deployments of the world's first service robots with
a sense of smell, powered by AI Nose, at seven industrial sites across Japan. In partnership with the world's leading provider
of semiconductor assembly and test services, we've expanded our collaboration and are targeting AI Nose applications across its
manufacturing footprints to enable real-time anomaly detection and process monitoring. We've also broadened our industrial footprint
through partnerships with two industrial automation specialists, both are Nvidia's smart factory ecosystem partners, aiming to
integrate AI-powered scent intelligence into smart factory and machine vision ecosystems across Asia."
our AI Nose platform has demonstrated impressive performance-achieving 85% accuracy in eldercare hygiene detection, 80% at Japanese
semiconductor facilities, and 90% in classifying food and beverage scents. These results validate the robustness and versatility of our
SLM across diverse environments. As a trainable AI for sent, I believe our SLM's accuracy will continue to improve as we scale."
executing a focused 90-day action plan to advance our SmellTech platform and unlock the next wave of AI-powered sensing. Aligned with
other 2H25 priorities, this positions us for scale-up in 2026. In addition to field tests with our robot customer in Japan, we will progress
through a multi-stage rollout roadmap with our semiconductor customer, targeting to complete approximately 1,400 pilot deployments of
AI Nose and then initiate Phase 1 expansion to around 5,000 units. This will lay the foundation for Phase 2 scale-up to as many as 15,000
units. We also plan to showcase the AI Nose-integrated robot with our partners at Automation Taipei in late August. We will also launch
pilot programs across our partners' target industrial sectors in Asia by 2H25. In parallel, we will initiate large-scale pilots
in Japan's senior care sector and evaluate expansion opportunities in Taiwan. To strengthen SLM performance, we will conduct broad-scale
validation and real-world testing. We will also actively pursue additional strategic partnerships in Asia and Europe for technology licensing
and regional commercialization."
our VELDONA immunotherapy programs, we continue to advance with capital discipline and strategic flexibility. We've begun
two human clinical trials in Taiwan-targeting HIV-related oral warts and primary Sj gren's syndrome-and reported
promising interim results from our veterinary study in feline chronic gingivostomatitis ("FCGS")."
a well-defined roadmap, we will implement our strategies with focus-expanding AI Nose pilots, enriching our Smell ID dataset, and
driving adoption across key verticals. As demand for intelligent environmental sensing accelerates, Ainos is uniquely positioned to provide
the missing link and lead the next frontier of AI-where machines can see, hear, and now, smell. Our leadership in AI Nose technology
and immunotherapy empowers us to seize immense growth opportunities and bring lasting value to our shareholders."
Lee, Chief Financial Officer of Ainos, remarked, "We're delighted with the strong momentum of our AI Nose platform, which
drove significant first-half revenue growth through our co-development project in Japan's senior care sector. We also improved
gross margin, turning to gross profitability in both Q2 and the first half. Our capital discipline narrowed first-half operating cash
outflows by 26% year over year, while we continued to invest in R&D, AI Nose validation, and clinical trials. With no debt maturities
through 2027 and measured use of our at-the-market facility generating $719K in net proceeds, we are supporting growth with a controlled
cost of capital. Our recent 1-for-5 reverse split, completed to regain Nasdaq compliance, further strengthens our capital structure and
better places us to attract institutional investors. Backed by this solid financial strategy, we remain well-equipped to advance key
strategic priorities and drive long-term growth."
Business Developments
has reached a pivotal inflection point, accelerating AI Nose commercial execution through pilot deployments, strategic partnerships,
and clinical validation across robotics, industrial, and healthcare sectors.
August 6, 2025, Ainos announced that it has secured a three-year subscription-based order valued at $2.1 million with ASE Technology
Holding Co., Ltd. ("ASEH"), the world's largest provider of semiconductor assembly and test services. The agreement
represents the first commercial success of Ainos' proprietary AI Nose platform in semiconductor manufacturing.
July 22, 2025, Ainos announced that ugo, its first robotics partner, will pilot the world's first service robots equipped with
AI Nose technology at seven sites across Japan. Powered by Ainos' proprietary SLM and Smell ID data insights, these ugo robots
will enable intelligent inspections, predictive maintenance, and environmental alerts across the pharmaceutical, industrial, and energy
July 16, 2025, Ainos announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq
Capital Market. The Company also unveiled a 90-day roadmap to scale its AI Nose platform in 2026, including the completion of a pilot
deployment of approximately 1,400 AI Nose units with ASEH and the launch of Phase 1 expansion to 5,000 units. Additional priorities include
showcasing the AI Nose-integrated ugo robot with Kenmec at Automation Taipei on August 20-23. Commercial efforts will focus on
expanding the SmellTech-as-a-Service (SaaS) model as a recurring revenue stream, enhancing SLM performance through expanded real-world
validation, and pursuing strategic partnerships in Asia and Europe for technology licensing and commercialization.
July 7, 2025, the Company announced a five-year distribution partnership with Solomon, a leader in machine vision, industrial AI, and
smart automation. The alliance aims to accelerate AI Nose adoption across key manufacturing sectors in Asia, including semiconductors,
petrochemicals, and autonomous mobile robots (AMRs). Solomon's visual language model (VLM) complements Ainos' SLM, enabling
advanced sensor fusion and expanding intelligent sensing applications.
June 27, 2025, Ainos announced the expansion of its strategic relationship with ASEH, the world's leading provider of semiconductor
assembly and test services. The companies are contemplating a multi-phase roadmap to deploy AI Nose across ASEH's global manufacturing.
The roadmap includes the deployment of approximately 1,400 units at ASEH and SPIL sites during the Evaluation Phase; an expansion to
5,000 units for integration across cleanrooms and production zones in Phase 1; and a full-scale rollout of up to 15,000 units in Phase
June 26, 2025, the Company announced a 1-for-5 stock consolidation to align its capital structure with its 2025 execution roadmap. The
action reduced the number of outstanding shares and proportionally increased the share price, with shareholder ownership percentages
remaining unchanged. This strategic move positions Ainos to attract broader institutional interest as it enters the commercial execution
phase in the second half of 2025 and supports its transition toward a recurring revenue
June 24, 2025, the Company announced a strategic partnership with Kenmec, a publicly listed Taiwanese leader in automation and system
integration. The alliance aims to scale Ainos' AI Nose and SLM technologies within Kenmec's smart factory ecosystem, accelerating
the deployment of multimodal sensory intelligence across robotics, logistics, infrastructure, and healthcare applications in Asia.
May 29, 2025, Ainos reported that its proprietary AI Nose improved its accuracy in detecting excretion-related odors from 80% to approximately
85%, based on 2,119 valid data entries collected from 254 participants in Japan and Taiwan. This milestone validates AI Nose as a viable,
non-contact solution for hygiene monitoring in long-term care ("LTC") settings and further reinforces the Company's
leadership in the emerging SmellTech category.
May 22, 2025, Ainos debuted its AI Nose platform at COMPUTEX 2025 in partnership with ugo. This milestone marked the first public demonstration
of real-time robotic olfaction-a new sensory category poised to transform smart robotics, environmental AI, and safety infrastructure.
May 19, 2025, Ainos announced promising interim results from its VELDONA clinical trial for FCGS. This randomized, controlled study
evaluates inflammation reduction, corticosteroid usage, and safety across 30 cats in high- and low-dose treatment groups. Interim results
show 10-44% symptom improvement and a potential steroid-sparing effect with no adverse events reported to date, indicating strong
commercial and scientific potential for a novel class of immunotherapy in companion animals. Final analysis is expected in mid-2026.
Nose digitizes scent into Smell ID, an AI-driven scent intelligence. This full-stack electronic nose (e-nose) platform combines precision
MEMS sensor arrays with proprietary AI algorithms, aiming to detect scent at parts-per-billion (ppb) sensitivity. Smell ID then converts
analog scent data into actionable insights, while the proprietary smell language model (SLM) learns complex scent patterns. Backed by
a 13-year scent data moat and deep medtech expertise, AI Nose aims to deliver continuous monitoring, predictive analytics, and instant
alerts to boost safety, quality, and efficiency. To be delivered as SmellTech-as-a-Service, it aims to offer subscription access to ongoing
scent intelligence, analytics, and real-time alerts, turning the invisible into strategic advantage.
Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and
smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics,